6Siddiqui N, Boddy AV, Thom as HD, et al. A clinical and phamaco - ki-netic study of the carboplation and paclitqaxel for epidieli-al ovariancer[J]. Br J Cancer, 1997, 75:287-297.
5Look KY. Epidemiology, etiology, and screening of ovarian cancer [C]//Rubin SC,Sutton GP ed. Ovarian cancer. Sec Ed. 2001 by Lippincott Williams and Wilkins, Philadelphia, 2001: 167- 180.
6McGuire WP. Primary chemotherapy for epithelial ovarian cancer [C]//Rubin SC,Sutton GP ed. Ovarian cancer. Sec Ed. 2001 by Lippincott Williams and Wilkins, Philadelphia, 2001 : 259- 271.
7Swart AM, on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part Ⅰ. Vol 25, No. 18S (June 20 Supplement), 2007: 5509.
8Kyrgiou M, Salami G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments [ J ]. J Natl Cancer Inst, 2006,98 : 1655- 1663.
9Bell J, Brady MF, Young RC ,et al. Randomized phase Ⅲ trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[ J]. Gynecol Oncol,2006, 102:432-439.
10Chan JK, Fleming G, Zhang M, et al. The potential benefit of six versus three cycles of chemotherapy in subsets of women with high-risk early-stage epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study[ J]. Gynecol Oncol, 2008, 108 : s3 abstract 4.
